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Abstract 
BACKGROUND: Limited body of evidence suggests that lipopolysaccharide of C. pneu-
moniae as well as C. pneumoniae-specific immune complexes can be detected and isolated from 
human serum. The aim of this study was to investigate the presence of viable elementary 
bodies of C.pneumoniae in serum samples of patients with acute coronary syndrome and 
healthy volunteers.  
MATERIAL AND METHODS: Serum specimens from 26 healthy volunteers and 56 pa-
tients with acute coronary syndrome were examined subsequently by serological 
(C.pneumoniae-specific IgA and IgG), PCR-based and bacteriological methods. Conventional, 
nested and TaqMan PCR were used to detect C.pneumoniae genetic markers (ompA and 16S 
rRNA) in DNA from serum specimens extracted with different methods. An alternative 
protocol which included culturing high-speed serum sediments in HL cells and further 
C.pneumoniae growth evaluation with immunofluorescence analysis and TaqMan PCR was 
established. Pellet fraction of PCR-positive serum specimens was also examined by immu-
noelectron microscopy.  
RESULTS: Best efficiency of final PCR product recovery from serum specimens has been 
shown with specific C. pneumoniae primers using phenol-chloroform DNA extraction pro-
tocol. TaqMan PCR analysis revealed that human serum of patients with acute coronary 
syndrome may contain genetic markers of C. pneumoniae with bacterial load range from 200 to 
2000 copies/ml serum. However, reliability and reproducibility of TaqMan PCR were poor for 
serum specimens with low bacterial copy number (<200 /ml). Combination of bacteriological, 
immunofluorescence and PCR- based protocols applied for the evaluating HL cells infected 
with serum sediments revealed that 21.0 % of the patients with acute coronary syndrome 
have viable forms C.pneumoniae in serum. The detection rate of C.pneumoniae in healthy vo-
lunteers was much lower (7.7%). Immunological profile of the patients did not match accu-
rately C.pneumoniae detection rate in serum specimens. Elementary bodies of C.pneumoniae 
with typical ultrastructural characteristics were also identified in serum sediments using 
immunoelectron microscopy. 
Conclusions: Viable forms C. pneumoniae with typical electron microscopic structure can be 
identified and isolated from serum specimens of the patients with acute coronary syndrome 
and some healthy volunteers. Increased detection rate of C. pneumoniae in serum among the 
patients with an acute coronary syndrome may contribute towards enhanced 
pro-inflammatory status in cardiovascular patients and development of secondary complica-
tions of atherosclerosis. 
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BACKGROUND 
Despite unquestionable role of C. pneumoniae in 
pathogenesis of respiratory infections there are many 
questions about involvement of the pathogen in de-
velopment other human diseases including atheros-
clerosis (1), multiple sclerosis (2,3), Alzheimer’s dis-
ease (4), lymphogranuloma (5), reactive arthritis (6), 
Guillain-Barre syndrome (7). The progress in that field 
is substantially complicated by the lack of standar-
dized criteria for laboratory diagnostics of chronic C. 
pneumoniae infection as well as contradictory infor-
mation about distribution of the pathogen throughout 
of the tissues of human body. 
Isolating and culturing of C. pneumoniae may 
represent significant challenge for non-specialized 
diagnostic labs. Several plasma serological markers 
have been recently proposed based on the results of 
proteomic analysis. In particular proteins encoded by 
Omp11, the PmpG family, IncA and by CpPLD are 
among promising candidates for immunological di-
agnostics of C. pneumoniae infection (8, 9). However, 
changed antigenic profile of C. pneumoniae during 
persistent colonization in human tissues (10, 11) un-
dermines the diagnostic value of serological markers. 
Among molecular diagnostic criteria used for 
detection of C. pneumoniae in human specimens are 
polymerase chain reaction (PCR), in-situ hybridiza-
tion method and enzyme immunoassay protocols (12, 
13). PCR-based approach usually targets parts of 
chlamydial genome, in particular genes encoding 16S 
rRNA, major outer membrane protein (OmpA), as 
well as Pst1 (13). 
However poor reproducibility limits signifi-
cantly the diagnostic importance of PCR and in-situ 
hybridization for non-respiratory specimens. Detec-
tion of chlamydial lipopolysaccharide in serum is 
claimed to improve reliability of molecular biology 
methods when used in addition to PCR and in situ 
hybridization protocols (12). 
There are multiple reports validating the pres-
ence of C. pneumoniae in respiratory secretion fluid, 
nasal, tracheal and lung tissues of the patients with 
inflammatory lung disease (13, 14, 15). Moreover, C. 
pneumoniae can efficiently propagate in blood cells, in 
particular in mononuclear cells and lymphocytes 
(16,17,18). The presence of C. pneumoniae in the blood 
cells predetermines the possibility of pathogen dis-
semination from respiratory system to different or-
gans and tissues. Besides respiratory organs C. pneu-
moniae can be detected in specimens from atheroscle-
rotic plagues (1, 19), cerebrospinal fluid (2) and en-
dothelium (20). 
In the present paper we report, that viable ele-
mentary bodies of C. pneumoniae with typical electron 
microscopic structure can be isolated from the serum 
samples of the patients with acute coronary syn-
drome. Furthermore, using combination of bacterio-
logical and PCR-based methods we show herein that 
patients with acute coronary syndrome have higher C. 
pneumoniae detection rate in serum as compared to 
healthy volunteers.  
MATERIAL AND METHODS  
Cell lines and bacterial strains 
HL cells (Washington Research Foundation, 
Seattle, USA) as well as C. pneumoniae (strain Kajaani 
6, K6) were kindly provided by Dr. P.Saikku (Univer-
sity of Oulu, Finland). HL cells were grown in RPMI 
1640 supplemented with 10% FCS at 37° C in 5% CO2. 
C.pneumoniae was initially propagated in HL cells and 
elementary bodies (EB) were purified by Renografin 
gradient centrifugation as widely described (21, 22). 
EB of C. pneumoniae were used as a reference for 
genetic and electron microscopy analysis. 
Patients and serum specimens.  
The study protocol was approved by the Ros-
tov-on- Don Medical University Ethics Committee. 
All patients were informed about the purpose of the 
study and have given written consent regarding par-
ticipation in the study. Initial observation has been 
done on the group of 18 patients with acute coronary 
syndrome (11 males and 7 females aged from 47 to 
68). Once conditions for combined microbiologic and 
nucleic acid amplification protocol were established, 
38 more patients with acute coronary syndrome (21 
males and 17 females, aged from 42 to 71) and 26 
healthy volunteers with no indication of cardiovas-
cular disease were enrolled (major groups of the 
study). Blood samples were collected into plastic 
tubes, kept at 37° C for 20 minutes and centrifuged at 
1000g, 4° C for 10 min. Resulting serum was imme-
diately separated and stored at - 80° C until assayed. 
C.pneumoniae-specific IgA and IgG antibodies 
were evaluated by using Chlamydia  pneumo-
niae-IgG-ELISA medac plus and Chlamydia pneumo-
niae-IgA-ELISA plus commercial kits with high-
ly  purified C.pneumoniae specific antigen without 
LPS. (Medac, Hamburg, Germany).  
Bacteriological assay.  
Tubes containing 3 ml of frozen serum samples 
were thawed on ice and subjected to the centrifuga-
t i o n  o n  B e c k m a n  c e n t r i f u g e  A N  ( B e c k m a n  C o u l t e r ,  Int. J. Med. Sci. 2010, 7 
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Inc., USA) at 16000 g for 45 min at 4° C. Obtained se-
diments were gently resuspended with micropipette 
in 1.0 ml of RPMI 1640 with 5% FCS, amphothericine 
B (5 µg/ml) and gentamycin (4 µg/ml). Resulting 
suspension was transferred to subconfluent mono-
layer of HL cells grown in 24- well plate. After inocu-
lation the plates were centrifuged at 1600g for 1 hour 
at 30° C and incubated for 2 h at 37° C in 5% C02. The 
medium was removed and replaced with fresh RPMI 
1640 supplemented with 1 µg/ml) of cycloheximide 
and plates were cultivated for 72 hours at 37° C in 5% 
CO2. 
A 24 well plate rather than 96 well plates was 
used in the study to avoid potential cross contamina-
tion. Each serum specimen inoculated into 24 well 
dish was followed by two wells filled with incubation 
medium alone. All manipulation with the plates were 
done without agitation. Positive control plates were 
set and examined by the end of each working day and 
were kept in separate incubator. Each plate examina-
tion procedure was followed by careful disinfection of 
the equipment. Positive findings were reconfirmed. 
The plates were evaluated for chlamydial 
growth by immunofluorescence microscopy with a 
Chlamydia genus-specific antibody against LPS prior 
to quantitative TaqMan- PCR for 16S rRNA of C. 
pneumoniae. Each isolate was passaged up to 3 times. 
Immunofluoresence staining.  
Infected HL monolayers grown on coverslips in 
24-well plates were fixed with methanol. Permebia-
lized cells were stained by direct immunofluoresence 
using FITC – conjugated monoclonal antibody against 
chlamydial lipopolysaccharide (NearMedic Plus, RF). 
Inclusion-containing cells were visualized using Ni-
kon Eclipse 50i microscope fluorescence microscope at 
x1350 magnification. 
DNA isolation.  
DNA isolation from whole serum  
Briefly, 1.0 ml of whole serum was mixed with 
0.5 ml of lysis buffer (0.2 M Tris-HCl buffer, pH 7,2 
supplemented with 0.5 % SDS) with 0.25 mg/ ml 
proteinase K (Promega, USA) and incubated for 2 
hours at 56° C. DNA from the resulting lysates was 
extracted using phenol-chloroform method as widely 
described (23) and precipitated with absolute ethanol. 
DNA pellet was finally resuspended in 25 µl of water. 
For comparison purpose bacterial DNA was extracted 
from the same volume of whole serum with QIAmp 
Blood Midi Kit (QIAGEN, Valencia, CA) according to 
the manual. 
Bacterial DNA was also extracted from the bac-
terial particles trapped from the whole serum with 
protein A from of Staph. aureus, insoluble (Sigma 
P7155). 1.0 ml of whole serum was mixed with 0.15 ml 
of protein A and incubated for 1 hour at 37 °C with 
occasional gentle shaking. The mixture was centri-
fuged for 5 min at 5000 g and DNA was extracted 
from the resulting pellet using QIAamp DNA Blood 
Mini Kit (QIAGEN INC., Valencia, Calif.) according to 
the manual.  
DNA isolation from infected HL cells  
Cells were harvested from 24 well plates and 
resuspended in 200 µl of lysis buffer and DNA was 
extracted using QIAamp DNA Blood Mini Kit 
(QIAGEN INC., Valencia, Calif.) according to the 
manual. 
DNA isolation from C.pneumoniae reference strain  
DNA was extracted from 100 µl of C. pneumoniae 
purified EB using reagents and protocol from QIAmp 
Blood Mini Kit (QIAGEN Inc., Valencia, Calif.). 
PCR.  
General Information 
Numerous precautions were employed to ensure 
validity of PCR protocols, especially nested PCR. 
Different work areas/rooms, different sets of the pi-
pets, barrier-filter tips and scrupulous clean-
ing/decontamination procedures were used. All 
samples were blinded for lab workers. Multiple con-
trols were used for PCR reactions. DNA extracted 
from C. pneumoniae reference strain (low concentra-
tion) and/or DNA extracted from the serum sediment 
of two C. pneumoniae infected patients were used as 
positive control. Positive control specimens were se-
lected using electron microscopy and serological as-
say. Serum specimens from serologically negative 
healthy volunteers with no C. pneumoniae EB detecta-
ble in serum sediments by electron microcopy were 
used as a negative control. Each PCR set was accom-
panied by a reaction mix with all PCR components 
except the target DNA. Positive findings were recon-
firmed.  
Conventional qualitative PCR.  
Briefly, 2 µl of DNA solution were transferred to 
the reaction mixture containing 1x PCR buffer (Silex, 
Moscow, RF) containing 10 mM Tris-HCl, pH 8,3 , 2.5 
mM MgCl2, 200  µM of each dNTPs, 1  U 
Taq-DNA-polymerase, 15 pmol of each primer. For-
ty-five cycles of amplification were performed on a 
PCR Thermocycler Perkin Elmer. Each cycle consisted 
o f  d e n a t u r a t i o n  s t e p  a t  9 4 ° C  f o r  4 5  s e c ,  p r i m e r  a n -
nealing at 63°C for 45 sec , primer extension at 72°C 
for 45 sec. Amplified product (10 µl) was visualized 
by electrophoresis in a 1.5% agarose gel with ethidium Int. J. Med. Sci. 2010, 7 
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bromide. Extracted DNAs were analyzed by PCR 
with primers CPN90-CPN91 specific for C. pneumoniae 
16S rRNA as described (24). 
Nested PCR. 
To ensure the specificity of PCR analysis a pro-
tocol for nested PCR for OmpA of C. pneumoniae was 
employed. The outer (oCP1 – 5’ 
TTACAAGCCTTGCCTGTAGG 3’, oCP2 – 5’ GCGA 
TCCCAAATGTTTAAGGC 3’) and nested (iCPC - 5’ 
TTATTAATTGATGGTACAATA 3’, iCPD - 5’ 
ATCTACGGCAGTAGTATAGTT 3’) primers were 
used as published (24). 
2 µl of DNA was added to reaction mixture 
containing 1x PCR buffer (Silex, Moscow, RF) con-
taining 10 mM Tris-HCl, pH 8,3 , 2.5 mM MgCl2, 15 
pmol of each primer, 200 µM of each of dNTPs and 
1 U of Taq polymerase. First run of amplification was 
conducted under cycling conditions consisting of an 
initial denaturation at 95°C for 5 min, followed by 
45 cycles of denaturation at 95°C for 30 sec, annealing 
at 63°C for 30 sec, and extension for 30sec at 72°C. For 
the second round of PCR, 2  µl of the first-round 
product was mixed with 23 µl of amplification mix-
ture containing primers for iCPC and iCPD and am-
plified using following cycling conditions: 35 cycles of 
denaturation at 95°C for 30 sec, annealing at 55°C for 
30 sec, and extension for 30sec at 72°C. PCR products 
were visualized by agarose electrophoresis with 
ethidium bromide. Taq DNA polymerase and other 
reagents for nested PCR were from Promega (UK). 
Quantitative TaqMan-PCR.  
For quantification purpose, Real-time PCR for 
16S rRNA of C. pneumoniae was conducted. PCR 
primers and TaqMan probe for 16S rRNA (GenBank 
accession  number  AF131889) were designed using 
Primer Express Software (Applied Biosystems, Foster 
City, CA, USA) and synthesized by Syntol (Moscow, 
RF). Designed primers and TaqMan probe (forward 
primer  СPN90, 5'-GGTCTCAACCCCATCCGT 
GTCGG-3'; reverse primer СPN91, 
5'-TGCGGAAAGCTGTATTTCTACAGTT-3'; and 
TaqMan probe 557, 5'-TCCAGGTAAGGTCC 
TTCGCGTTGCATCG-3') generated a PCR product of 
predicted size (194 bp). The TaqMan probe was la-
belled at the 5' end with 6-carboxyfluorescein as the 
reporter dye and at the 3' end with 
6-carboxytetramethylrhodamine as the quencher. An 
additional BLAST search analysis was conducted to 
unsure specificity of the primers and probe. Real-time 
PCR was performed with the iCycler IQ ystem (Bio-
rad, USA). 2 µl of extracted DNA was analyzed with 
the PCR mixture in a total volume of 25 µl. The PCR 
mixture consisted of 10 mM Tris (pH 8.3), 50 mM KCl, 
1,5 mM MgCl2, 200 µM of each dNTPs, 2,5 U of Ter-
mostar Taq DNA polymerase (Syntol, Moscow, RF); 
and 5pmol of both forward and reverse primers and 
3,5 pmol probe. The real-time PCR run was 10 min at 
95°C, and 50 repeats of 20 sec at 95°C and 50 sec at 
62°C. All samples were analyzed in triplicates. A 
sample was considered positive if three of three assay 
results were positive in the triplicate test and if the 
average value for the PCR run was greater than or 
equal to 1.0. 
Amounts of 16S rRNA are represented bellow in 
16S rRNA genome equivalents per ml of serum. Cali-
brator standards were prepared using 194 bp 16S 
rRNA DNA fragment of C pneumoniae cloned into the 
pGEM-T plasmid vector (pVU56) using the TA clon-
ing kit (Invitrogen, San Diego, CA) similarly to Broc-
colo F (25).  
The cycle threshold (CT) values, defined as the 
number of cycles at which the fluorescence of the re-
porter dye first exceeds the calculated  background 
level, were automatically estimated by the instrument 
for each reaction. CT values for serum samples were 
plotted against calibrator standards of cloned DNA 
fragment.
  
Electron Microscopy. 
Thawed serum samples (10 ml) were spun at 
16000g for 60 min. Resulting pellets were analyzed by 
TaqMan PCR for C. pneumoniae 16S rRNA. Positive 
specimens were fixed for 4 hours in phosphate buffer 
(pH 7.8) containing 5% glutaraldehyde, post-fixed in 
1% osmium tetroxide for 1 hour, dehydrated in etha-
nol and embedded in LR White resin (EMS, USA). 
Stained ultrathin sections (200-300Аº) were evaluated 
by electron microscopy using JEM-100B microscope 
(Japan Electron Optics Laboratory Co., Tokyo, Japan). 
Purified EB of C. pneumoniae reference strain were 
used as positive control for electron microscopy stu-
dies. PCR-negative sediments of serum obtained from 
healthy volunteers served as negative control. 
Immunoelectron microscopy was performed in 
specimens fixed with 2% paraformaldehyde and 0.1 % 
glutaraldehyde in PBS (7.5) with further contrasting 
with 2% uranyl acetate. Acetone-dehydrated speci-
mens were embedded into LR White Resin for ultra-
thin sectioning. The sections were blocked for 1 hour 
with 0.5% bovine serum albumin in PBS and incu-
bated overnight with monoclonal antibody against 
chlamydial lipopolysaccharide (NearMedic Plus, RF). 
After washing in PBS sections were incubated for 2 
hours with goat anti-mouse IgG conjugated with 10 
nm colloid gold (Invitrogen, USA) and contrasted 
with uranyl acetate. Sections were examined with a Int. J. Med. Sci. 2010, 7 
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Joel 100B (Japan) electron microscope. Control sec-
tions were incubated with normal mouse IgG. 
RESULTS 
Initial observation took place when we obtained 
sera from 18 patients with ACS and analyzed them for 
presence of C. pneumoniae specific IgG and IgA using 
ELISA Medac kit (Germany) as well as for presence of 
genomic determinants of C. pneumoniae. As can be 
seen from Table 1, 7 patients from the initial group 
were positive for C. pneumoniae-specific IgG, whereas 
4 patients had diagnostically relevant levels of IgA. 
Simultaneous detection of increased titers of IgG and 
IgA was documented only in 4 patients. Surprisingly, 
when DNA specimens extracted from 1.0 ml of serum 
aliquots were analyzed for presence of 16S rRNA by 
conventional PCR, we have found that 5 patients with 
ACS were positive for the genetic marker of C. pneu-
moniae. Finally, just 3 patients (out of 18) had in-
creased levels of two Ig isotypes and positive signal in 
conventional PCR for 16S rRNA. Such inconsistency 
between serologic and genetic markers of C. pneumo-
niae infection is well known and widely discussed (1). 
However, detectability of the genetic marker of C. 
pneumoniae in human serum appeared to be a rea-
sonably intriguing finding. Therefore, we decided to 
optimize conventional PCR protocol for detection of 
the C. pneumoniae genetic markers in serum.  
PCR-positive sera obtained from 2 randomly se-
lected ACS patients were used for this purpose. As 
can be seen from Figure 1, there is an obvious increase 
in the final recovery of 194 bp PCR product (16S 
rRNA amplicon) when phenol-chloroform DNA ex-
traction protocol has been used. Somehow QIAmp 
Midi Extraction kit (Qiagen) showed lower recovery 
rate of final PCR product which can be explained by 
lower efficiency of C. pneumoniae DNA extraction. 
Sufficient recovery of final PCR product has been also 
seen when protein A from Staph. aureus has been 
used for isolation of C pneumoniae from whole serum. 
This fact may suggest that extracted DNA originates 
rather from intact chlamydial particles opsonized by 
immunoglobulins, than remnants of C. pneumoniae 
circulating in the blood. 
To confirm the results obtained with conven-
tional PCR and insure its specificity we compared 
side-by-side two amplification reactions with phe-
nol-chloroform extracted C. pneumoniae DNA. One 
has been conducted with protocol using primers spe-
cific for 16S rRNA, another one – with the primers for 
ompA in nested PCR format. As can be seen from 
Figure 2, the sensitivity of PCR reaction was similar 
regardless of the primer set used. 
 
Table 1. C.pneumoniae positivity status assessment using serological, RT- PCR and bacteriological analysis of serum spe-
cimens 
GROUPS 
 
Total Number of individuals Positive in: 
    Serological assay  TaqMan PCR in 
serum 
Bacteriological assay with 
further PCR validation  IgA  IgG 
PRELIMINARY GROUP   Patients with ACS   18  4  7  5  3 
MAYOR GROUPS   Healthy volunteers   26 
 
1  4  -  2 
Patients with ACS   38  6  13 
 
-  8  
 
 
 
 
Figure 1. Recovery of PCR product in DNA samples isolated from serum specimens using QIAamp DNA blood midi kit, 
protein A and phenol-chloroform extraction method. 1 – molecular size standards; 2, 6 and 10 – PCR-positive serum from 
patient M; 3, 7 and 11 – PCR-positive serum from patient P; 4, 8 and 12 – PCR negative serum from patient S; 5, 9 and 13 – 
extraction control; 14 – negative control; 15 – positive control. Int. J. Med. Sci. 2010, 7 
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Figure 2. Recovery of PCR products in amplification reactions with different primers (chlamydial 16 S rRNA and omp1) 
using DNA extracted from human plasma by phenol-chloroform method. 1 – molecular size standards; 2, and 8 – PCR 
positive serum from patient M.; 3 and 9 – PCR positive serum from patient P.; 4 and 10 – PCR negative serum from patient 
S.; 5 and 11 - extraction control; 6 and 12 – negative controls; 7 and 13 – positive controls.  
 
 
Next, we decided to employ TaqMan PCR pro-
tocol for quantification of C. pneumoniae DNA ex-
tracted from serum specimens with phe-
nol-chloroform method. Standard curves were made 
using incremental dilutions of reference plasmid 
containing the primer-spanning region of C. pneumo-
niae 16S rRNA gene. These standard plasmid dilutions 
covered the range of plasmid concentration corres-
ponding from 5 to 1,0 6 copies/µl. According to the 
results obtained from the initial group, 5 serum spe-
cimens obtained from the patients with ACS had a 
positive TaqMan PCR assay with variations in bac-
terial load from 200 to 2000 copies/ml of serum. 
However 2 serum specimens with lowest copy num-
bers (<300 copies/ml) had inconsistent PCR readings 
with CT values exceeding 30 cycles on two or more 
different attempts. Thus, TaqMan assay validates the 
presence of C.pneumoniae DNA in the serum samples 
of the patients with ACS. However it is clear that 
TaqMan PCR is associated with some sensitivity and 
reproducibility issues when C. pneumoniae is present 
in serum specimens at low copy number.  
To confirm the presence of C pneumoniae in se-
rum specimens obtained from the patients with ACS 
we also used ultrastructural analysis. 16000g serum 
sediments from two patients were analyzed first by 
TaqMan assay and further electron microcopy me-
thod. As can be seen from Figure 3, 16000 g pellet 
fraction contained visually intact pear shaped elec-
tron-dense structures approximately 0.3 microns in 
diameter similar to elementary bodies of C. pneumo-
niae reference strain. Both serum sediments were pos-
itive in TaqMan PCR assay as well. Therefore, electron 
microscopy analysis supports PCR data demonstrat-
ing the presence of C. pneumoniae in serum specimens 
of the patients with ACS. The identity of ultrastruc-
tures in serum sediments was confirmed by im-
mune-gold labeling protocol (Figure 4). However ob-
tained results do not answer a question about viability 
of C. pneumoniae particles present in the serum spe-
cimens. 
To address this issue we decided to implement a 
combination of classical bacteriological protocol and 
nucleic acid amplification method in detection of C. 
pneumoniae in serum specimens of ACS patients. Sta-
tistically representative group of ACS patients (Table 
1, clinical trial group) as well as age- and sex-matched 
control group were used for this purpose. According 
to the results diagnostically relevant levels of IgG for 
C. pneumoniae were found in 34.2% of the patients 
with ACS, whereas IgA positive were seen just in 
19.7% of the ACS patients. Simultaneous detection of 
increased IgG and IgA took place just in 13.1 % of the 
ACS patients. Control group had a lower detection 
rate for both IgG and IgA (19.3% and 3,8% respec-
tively).  
16000 g pellet fraction of serum specimens ob-
tained from 38 patients with ACS were resuspended 
and inoculated into cycloheximide-treated HL cells 
for further culture assay and immunofluroscence 
analysis with chlamydial LPS-specific antibody. A 
total of 8 specimens from ACS patients were positive 
for chlamydial growth with LPS-specific antibody 
revealing the presence of viable C. pneumoniae in se-
rum. Positive immunofluorescence was usually seen 
within 72 hours after specimen inoculation. Inclusions 
varied in size and staining but were generally much 
smaller, than usually seen in case of C. pneumoniae 
infection in cultured cells and had reduced intensity 
of immunofluorescent staining (Figure 5) resembling 
those reported during persistent C pneumoniae infec-
tion in presence of IFN-γ (26). 
All 10 serum isolates survived at least 2 passages 
and were tested positive by 16S rRNA TaqMan-PCR 
assay, suggesting the identity of the isolates as C. 
pneumoniae. Just two serum specimen obtained from 
the control group had been confirmed to be positive 
for C.pneumoniae by culture assay and PCR analysis Int. J. Med. Sci. 2010, 7 
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despite of lack diagnostically relevant titers of IgG 
and IgA. Only 4 patients with ACS were assessed 
positively by both bacteriological protocol and Medac 
IgG-IgA assay.  
 
 
 
 
Figure 3. Electron-microscopic images of C.pneumoniae elementary bodies obtained from HL cells infected with C. 
pneumoniae reference strain (A and B) and serum centrifugates (C and D). 
 
 
 
 
 
Figure 4. Electron-microscopic images. Immunogold labeling of C.pneumoniae elementary bodies in serum sediments. A – 
preincubation with normal mouse IgG. B – preincubation with monoclonal antibody against chlamydial LPS. Int. J. Med. Sci. 2010, 7 
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Figure 5. Immunofluoresence analysis of HL monolayers after inoculation of serum sediments (A), and reference culture 
(B) of C. pneumoniae. 
 
DISCUSSION 
C. pneumoniae is an obligate intracellular respi-
ratory pathogen which can be identified in different 
tissues and organs. Dissemination of the pathogen is 
believed to be mediated by peripheral blood mono-
nuclear cells known to harbor viable chlamydial par-
ticles (27). It is possible to culture C. pneumoniae from 
monocytes of cardiovascular patients suggesting that 
the ability to form virulent elementary bodies is not 
lost within the mononuclear cell (28). However, the 
elementary bodies of C. pneumoniae have never been 
found in free circulation within the bloodstream or 
any other bodily fluid except cerebrospinal fluid (2).  
The major conclusion from the results presented 
above is that viable and virulent forms of C. pneumo-
niae can be isolated from the human serum. Despite 
atypical visual appearance of the inclusion bodies, the 
isolates can infect, survive and multiply in the host 
cells accomplishing full cycle of chlamydial infection. 
Moreover, genetic markers of C. pneumoniae (16S 
rRNA and omp1) as well as ultrastructures identified 
by immunoelectron microscopy as elementary bodies 
of Chlamydia spp. can be detected and in the human 
serum. These results were supported by nested PCR 
protocol and TaqMan PCR assay. The later revealed 
that chlamydial load in serum specimens varies 
among the individuals in the range of 200-2000 cop-
ies/ml of serum. The performance of nucleic acid 
amplification protocols used in our studies was highly 
dependable on the method DNA extraction and bac-
terial load value in the serum specimens. In particular, 
regardless of targeted sequence (16S rRNA or omp1), 
best PCR performance has been achieved with DNA 
extracted with phenol-chloroform protocol, whereas 
TaqMan PCR sensitivity became unsatisfactory at low 
values of bacterial load. On the other hand, serum 
contains many PCR inhibitors (29) which undermines 
the usage of quantitative PCR in direct testing of se-
rum specimens. Therefore, in the current attempt to 
evaluate the prevalence of C pneumoniae bacteremia in 
cardiovascular patients we used a combination of cell 
culture technique with further evaluation of isolates 
by PCR. That approach confirmed our preliminary 
results and allowed us to find, that 21% of the patients 
with ACS appear to be positive for presence of C. 
pneumoniae in serum specimens. Much lower detec-
tion rate has been seen in control group (7.6%). Un-
fortunately, detectability of C. pneumoniae in serum 
specimens is in controversial agreement with seropo-
sitivity rate in Medac IgG and IgA assay. Currently, 
IgA level is considered to be indicative of active pa-
thogen due to the short life of IgA (30). Nevertheless 
even this parameter alone does not match accurately 
the status of exposure of the patients to C. pneumoniae 
measured by cell culture test with further PCR.   
To our best knowledge, our manuscript is a first 
communication reporting the isolation of C. pneumo-
niae from serum specimens. However, there are some 
other communications supporting indirectly our 
finding. In particular, it is well known that human 
serum contains detectable amounts of chlamydial LPS 
and  C. pneumoniae-specific immune complexes (12, 
31). In our view, serum-associated LPS is likely to 
derive from partially destroyed cell walls and appar-
ently from intact elementary bodies of C. pneumoniae. 
However, we have to acknowledge that our re-
sults do not resolve any current problems in labora-
tory diagnostics of chlamydial infection. The protocol 
used in our study is hardly adjustable to routine work 
in regular diagnostic laboratory since it requires cul-
tured cells and significant volumes of serum. A sensi-
tive PCR protocol is urgently in need for quantifica-
tion of chlamydial bacterial load in clinical specimens. Int. J. Med. Sci. 2010, 7 
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Some other questions need to be addressed in future 
research. First of all, our results do not reveal the ori-
gin of chlamydial particles in human serum. It is 
possible, that they may originate from destructed 
mononuclear cells and/or macrophages residing in 
the atherosclerotic plaques. However regardless of the 
origin, we can claim that the presence of virulent 
chlamydial particles in serum is an apparent sign of C. 
pneumoniae circulation in the bloodstream and may 
represents a new potential mechanism of the patho-
gen generalization throughout the human body. At 
the same time, we realize disputable relevance of our 
results to pathogenesis and clinical manifestations of 
atherosclerosis. The finding of C. pneumoniae in serum 
of ACS patients does not establish causality for the 
pathogen in development of atherosclerosis. Howev-
er, increased positivity rate for presence of C. pneu-
moniae in serum among ACS patients is very likely to 
contribute towards enhanced pro-inflammatory sta-
tus in cardiovascular patients and development of 
secondary complications of atherosclerosis. 
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